Neuroleptic malignant syndrome with Latuda
Neuroleptic malignant syndrome has been added as a rare adverse event in the summary of product characteristics for Latuda (lurasidone; Sunovion).
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069253
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com